Biologic Treatment Modification Efficacy in Concurrent Inflammatory Bowel Disease and Ankylosing Spondylitis: A Retrospective Cohort Study at a Single Tertiary Center

Background: The link between ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) is well-established, with concurrent prevalence estimates ranging from 5–10%. However, there are still significant gaps in our understanding, and a comprehensive treatment guideline for these co-diagnosed p...

Descripción completa

Detalles Bibliográficos
Autores principales: Savin, Einat, Ben-Shabat, Niv, Levartovsky, Asaf, Lahat, Adi, Omar, Mahmud, Gendelman, Omer, Lidar, Merav, Watad, Abdulla, Ben-Horin, Shomron, Kopylov, Uri, Sharif, Kassem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672021/
https://www.ncbi.nlm.nih.gov/pubmed/38002764
http://dx.doi.org/10.3390/jcm12227151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672021/
https://www.ncbi.nlm.nih.gov/pubmed/38002764
http://dx.doi.org/10.3390/jcm12227151

Ejemplares similares